Norgesic (Orphenadrine Citrate, Paracetamol)

Orphenadrine citrate and paracetamol, the active ingredients in Norgesic, are a muscle relaxant and analgesic presented as tablets for oral use. They treat muscle spasm and associated pain in adults.\nGNH India supplies Norgesic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norgesic combines a centrally acting muscle relaxant with an analgesic to address conditions involving muscle spasm and pain.\n\nMuscle spasm: provides relief of involuntary muscle contraction and associated discomfort.\nMusculoskeletal pain: reduces pain arising from joints, ligaments and soft tissues.\nBack pain: alleviates acute low‑back pain episodes.\nAcute pain: manages short‑term pain following injury or surgery.

Common Side Effects:\n- Drowsiness: feeling of sleepiness or reduced alertness.\n- Dry mouth: decreased salivation leading to a dry oral cavity.\n- Dizziness: sensation of light‑headedness or unsteadiness.\n- Blurred vision: temporary loss of visual sharpness.\n- Nausea: feeling of queasiness or urge to vomit.\n- Constipation: reduced bowel movements or hard stools.\n\nSerious or Rare Side Effects:\n- Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Hepatotoxicity: liver injury indicated by elevated enzymes or jaundice.\n- Cardiac arrhythmia: abnormal heart rhythms, especially in predisposed patients.\n- Urinary retention: difficulty emptying the bladder.\n- Anaphylaxis: rapid, severe allergic reaction with airway compromise.\n- Blood dyscrasias: abnormal blood cell counts including agranulocytosis.

Before initiating therapy, consider the following precautions.\n\nLiver function assessment: evaluate hepatic status due to paracetamol metabolism.\nGlaucoma caution: avoid in patients with narrow‑angle glaucoma because of anticholinergic effects.\nConcomitant CNS depressants: monitor for enhanced sedation when combined with alcohol or other sedatives.\nUrinary retention risk: be vigilant in patients with prostatic hypertrophy or bladder outlet obstruction.\nAlcohol use: limit intake as it may increase hepatotoxic potential.\nStore at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Norgesic may interact with several medicines; review the following categories.\n\nMajor Interactions (Avoid):\n- MAO inhibitors: risk of hypertensive crisis when combined.\n- Other anticholinergics: additive anticholinergic burden leading to severe dry mouth, constipation, or confusion.\n- Hepatotoxic drugs (e.g., isoniazid, methotrexate): increased risk of liver injury.\n- Alcohol: potentiates sedation and liver toxicity.\n- CNS depressants (opioids, benzodiazepines): enhanced central nervous system depression.\n\nModerate Interactions (Monitor Closely):\n- CYP450 inhibitors (e.g., fluconazole): may raise paracetamol plasma levels.\n- CYP450 inducers (e.g., rifampicin): may reduce therapeutic effect.\n- Warfarin: possible increase in bleeding tendency.\n- Antihypertensives: additive hypotensive effect.\n- Diuretics: may exacerbate urinary retention.